Avendus Future Leaders Fund III (Avendus) has acquired a stake in Aragen Life Sciences Limited (formerly GVK Biosciences) from Reddy Investment Trust through a secondary purchase. The transaction also involved a parallel investment by SBI Life Insurance Company Limited, which acquired a stake in Aragen from Reddy Investment Trust.
This acquisition highlights growing investor interest in India’s contract research, development, and manufacturing organization (CRDMO) space, which continues to see strong demand from global pharmaceutical and biotech companies.
Also Read: JSW Steel Acquires Saffron Resources — CAM Advises
Parties Involved
Investor: Avendus Future Leaders Fund III
Other Investor: SBI Life Insurance Company Limited
Seller: Reddy Investment Trust
Target: Aragen Life Sciences Limited (formerly GVK Biosciences)
Legal Counsel to Avendus: JSA Advocates & Solicitors
Legal Counsel & Deal Team
JSA Advocates & Solicitors advised Avendus Future Leaders Fund III on this transaction.
Sidharrth Shankar, Partner
Prakriti Jaiswal, Partner
Rishika Agarwal, Senior Associate
Eksha Narayan, Senior Associate
Mahi Jaiswal, Associate
The JSA team provided comprehensive legal support on structuring, drafting, negotiation, and finalisation of the definitive documentation.
About the Target
Aragen Life Sciences Limited is one of India’s leading fully integrated CRDMOs, offering end-to-end contract services across the drug development cycle — from discovery and development to commercial manufacturing. Aragen serves both small molecules and biologics, catering to global pharmaceutical and biotechnology companies.
With deep expertise in research and manufacturing, Aragen is positioned as a trusted partner for global pharma R&D, delivering services that accelerate time-to-market for novel therapies.
Strategic Significance
Expanding CRDMO Investments: Investor appetite for contract research and manufacturing in India is rising due to the country’s cost-efficient capabilities, skilled talent pool, and growing role in the global pharmaceutical supply chain.
Strengthening Avendus Portfolio: The stake in Aragen aligns with Avendus’ strategy of backing high-growth Indian companies with global competitiveness.
Diversification of Investors: Participation by SBI Life Insurance highlights increasing institutional investor confidence in India’s pharma and biotech services sector.
Why It Matters
This transaction reflects the strength and resilience of India’s life sciences industry, which continues to attract capital from private equity and institutional investors. With CRDMOs playing a critical role in global drug discovery and manufacturing, deals like this position Indian companies at the center of the global pharma value chain.
Also Read: Chemours and SRF Forge Strategic Fluoropolymer Supply Pact — CAM & AZB Advise
For more legal deal updates and analysis, stay tuned to TheCourtroom.in
Disclaimer
This article is for informational purposes only and does not constitute legal or financial advice. Readers should consult professionals before making decisions.
